Najnowsze wersje próbne


EudraCT Number: 2022-001476-33 Sponsor Protocol Number: D5985C00003 Start Date: 2022-11-02
Sponsor Name: AstraZeneca AB
Full Title: A Randomized, Double-Blind, 12-Week (with an Extension to 52 weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF)...
Medical condition: Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Disease: Version SOC Term Classification Code Term Level
21.1 100000004855 10010952 COPD LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: BG (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-000253-92 Sponsor Protocol Number: EHP-101-MS02 Start Date: 2022-10-14
Sponsor Name: Emerald Health Pharmaceuticals Inc.
Full Title: A Phase IIa, Open-label, Multicentre Dose-Finding Trial in Patients with Relapsing Forms of Multiple Sclerosis (RMS) to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101
Medical condition: Relapsing Forms of Multiple Sclerosis (RMS)
Disease: Version SOC Term Classification Code Term Level
21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
Population Age: Adults Gender: Male, Female
Trial protocol: ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-002905-89 Sponsor Protocol Number: 20186 Start Date: 2022-10-06
Sponsor Name: Bayer AG
Full Title: An 18-month, open-label, single-arm safety extension study of an age-and bodyweight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults f...
Medical condition: Treatment of children with chronic kidney disease and proteinuria
Disease: Version SOC Term Classification Code Term Level
23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
20.1 10038359 - Renal and urinary disorders 10037032 Proteinuria PT
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
Trial protocol: ES (Ongoing) BE (Ongoing) NL (Ongoing) AT (Ongoing) DK (Ongoing)
Trial results: (No results available)

EudraCT Number: 2020-006072-32 Sponsor Protocol Number: 2019/ABM/01/00078 Start Date: 2022-10-05
Sponsor Name: Heliodor Święcicki Clinical Hospital of the Poznań University of Medical Sciences
Full Title: Pulmonary REsistance modification under treatment with Sacubitil/valsartaN in paTients with HeartFailure with reduced ejection fraction
Medical condition: Heart Failure with reduced ejection fraction.
Disease: Version SOC Term Classification Code Term Level
20.0 100000004849 10078289 Heart failure with reduced ejection fraction LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: PL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-006326-48 Sponsor Protocol Number: CO43810 Start Date: 2022-09-27
Sponsor Name: Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
Full Title: A PHASE I/II, OPEN-LABEL, SINGLE-ARM, TWO-PART TRIAL TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF GLOFITAMAB IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN PEDIATRIC AN...
Medical condition: CD20 positive B-Cell Non-Hodgkin Lymphoma
Disease: Version SOC Term Classification Code Term Level
23.1 100000004864 10084346 B-cell non-Hodgkin's lymphoma LLT
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
Trial protocol: ES (Ongoing) DK (Ongoing) DE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-003087-27 Sponsor Protocol Number: ARGX-113-2009 Start Date: 2022-09-26
Sponsor Name: argenx BV
Full Title: A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
Medical condition: Bullous Pemphigoid
Disease: Version SOC Term Classification Code Term Level
21.1 100000004858 10006567 Bullous pemphigoid LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) HU (Ongoing) ES (Ongoing) GR (Ongoing) BG (Ongoing) NL (Ongoing) HR (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-003380-95 Sponsor Protocol Number: CDYP688A12101 Start Date: 2022-09-20
Sponsor Name: Novartis Pharma AG
Full Title: A Phase I/II, multi-center, open label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas
Medical condition: MUM and other non-uveal, GNAQ/11 mutant melanomas
Disease: Version SOC Term Classification Code Term Level
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081431 Uveal melanoma PT
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
20.0 100000004853 10030052 Ocular melanomas HLT
Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-005504-36 Sponsor Protocol Number: ABNCoV2-03 Start Date: 2022-09-19
Sponsor Name: Bavarian Nordic A/S
Full Title: Evaluation of the Immunogenicity, Safety, and Tolerability of a Single Dose of ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2: a Phase 3 Trial in Two Parts—Randomized, Doubl...
Medical condition: COVID-19 disease
Disease: Version SOC Term Classification Code Term Level
23.1 10042613 - Surgical and medical procedures 10084457 COVID-19 immunisation PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DK (Ongoing) BE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-005071-40 Sponsor Protocol Number: AVT03-GL-C01 Start Date: 2022-09-05
Sponsor Name: Alvotech Swiss AG
Full Title: A Randomized, Double-Blind, Parallel Design, Repeat Dose, 2-arm, Multicenter Study Comparing the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profiles of AVT03 and US-Prolia® in Postmenopa...
Medical condition: Osteoporosis
Disease: Version SOC Term Classification Code Term Level
20.0 10028395 - Musculoskeletal and connective tissue disorders 10031282 Osteoporosis PT
Population Age: Adults, Elderly Gender: Female
Trial protocol: BG (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-000271-39 Sponsor Protocol Number: 2022-01 Start Date: 2022-09-02
Sponsor Name: Adeptio Pharmaceuticals Ltd
Full Title: Single-arm, open-label dose titration phase 2 clinical trial of (+)-α-DHTBZ for the treatment of tardive dyskinesia (TD)
Medical condition: Tardive dyskinesia
Disease: Version SOC Term Classification Code Term Level
21.1 10029205 - Nervous system disorders 10043118 Tardive dyskinesia PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: HR (Ongoing)
Trial results: (No results available)